Claude Biosecurity Controls for Pharma: 2026 Analysis
A 2026 governance framework for AI assistants in pharma and biotech R&D, covering WHO BRIET guidance, project approvals, monitoring, evidence retention, metrics, and tabletop testing.
Back to Articles
Articles tagged with “pharma-ai-governance”
Claude Enterprise Pharma Data Security: EFS Analysis
A 2026 analysis of Claude Enterprise pharma data security, including EFS customer-owned storage, retention and HIPAA boundaries, rollout questions, and a cloud-cost worksheet.
AI Governance in Biotech: Council Charter and Decision Rights
A 2026 analyst guide to AI governance in biotech: council charter templates, decision rights (RACI), FDA/EMA principles, EU AI Act deadlines, and six company case studies.
How to Build an AI Center of Excellence in Biotech (2026)
A 2026 analyst guide to building an AI Center of Excellence in biotech: hub-spoke-hybrid models, FDA/EMA/NIST governance, staffing budgets from $2M to $200M, and named cases from Sanofi, Merck, Novartis, AstraZeneca, and GSK.